1. Home
  2. SCLX vs REFR Comparison

SCLX vs REFR Comparison

Compare SCLX & REFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • REFR
  • Stock Information
  • Founded
  • SCLX 2011
  • REFR 1965
  • Country
  • SCLX United States
  • REFR United States
  • Employees
  • SCLX N/A
  • REFR N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • REFR Multi-Sector Companies
  • Sector
  • SCLX Health Care
  • REFR Miscellaneous
  • Exchange
  • SCLX Nasdaq
  • REFR Nasdaq
  • Market Cap
  • SCLX 51.3M
  • REFR 48.3M
  • IPO Year
  • SCLX N/A
  • REFR N/A
  • Fundamental
  • Price
  • SCLX $0.23
  • REFR $1.14
  • Analyst Decision
  • SCLX Strong Buy
  • REFR
  • Analyst Count
  • SCLX 4
  • REFR 0
  • Target Price
  • SCLX $14.00
  • REFR N/A
  • AVG Volume (30 Days)
  • SCLX 1.1M
  • REFR 29.7K
  • Earning Date
  • SCLX 05-12-2025
  • REFR 03-06-2025
  • Dividend Yield
  • SCLX N/A
  • REFR N/A
  • EPS Growth
  • SCLX N/A
  • REFR N/A
  • EPS
  • SCLX N/A
  • REFR N/A
  • Revenue
  • SCLX $56,590,000.00
  • REFR $1,335,531.00
  • Revenue This Year
  • SCLX $24.19
  • REFR N/A
  • Revenue Next Year
  • SCLX $109.90
  • REFR N/A
  • P/E Ratio
  • SCLX N/A
  • REFR N/A
  • Revenue Growth
  • SCLX 22.02
  • REFR 46.83
  • 52 Week Low
  • SCLX $0.21
  • REFR $1.10
  • 52 Week High
  • SCLX $2.30
  • REFR $2.41
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 36.43
  • REFR 42.13
  • Support Level
  • SCLX $0.22
  • REFR $1.11
  • Resistance Level
  • SCLX $0.29
  • REFR $1.22
  • Average True Range (ATR)
  • SCLX 0.03
  • REFR 0.07
  • MACD
  • SCLX -0.00
  • REFR 0.00
  • Stochastic Oscillator
  • SCLX 25.59
  • REFR 31.25

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About REFR Research Frontiers Incorporated

Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. Its revenue source comes from the licensing of technology.

Share on Social Networks: